雷利度胺联合地塞米松方案治疗多发性骨髓瘤疗效观察  

Clinical Efficacy of Ralidomide Combined with Dexamethasone in Treatment of Patients with Multiple Myeloma

作　　者：白培清 杨雷[1] 宫敬智 孙小燕 金建刚 张维莲[1] 郜小岳 秦玉柱 BAI Pei-qing;YANG Lei;GONG Jing-zhi;SUN Xiao-yan;JIN Jian-gang;ZHANG Wei-lian;GAO Xiao-yue;QIN Yu-zhu(Department of Hematology,81 Army Group Hospital of PLA Army,Zhangjiakou,Hebei 075000,China;Department of Internal Medicine,the First Hospital of Zhangjiakou,Zhangjiakou,Hebei 075000,China)

机构地区：[1]中国人民解放军陆军第八十一集团军医院血液内科,河北张家口075000 [2]张家口市第一医院内科,河北张家口075000

出　　处：《解放军医药杂志》2020年第1期47-50,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：河北省卫生厅科研基金项目(20181552);张家口市科学技术研究与发展计划项目(1712001D)

摘　　要：目的观察雷利度胺联合地塞米松方案治疗多发性骨髓瘤(MM)的临床疗效。方法选择2016年3月—2018年10月我科收治的MM患者79例,根据治疗方法分为对照组39例和观察组40例。2组均给予地塞米松治疗方案,对照组应用硼替佐米治疗,观察组给予雷利度胺治疗。观察2组治疗效果,比较红细胞、血红蛋白、白细胞和血小板、血清肌酐、血清M蛋白和骨髓浆细胞变化情况,并评估药物不良反应。结果观察组总有效率高于对照组(P<0.05)。治疗后2组血红蛋白、红细胞、血小板较治疗前升高,血肌酐、血清M蛋白和骨髓浆细胞较治疗前减低,且观察组改善情况优于对照组(P<0.05)。2组药物不良反应发生率比较差异无统计学意义(P>0.05)。结论雷利度胺联合地塞米松方案治疗MM效果明显。Objective To observe clinical efficacy of Ralidomide combined with Dexamethasone in treatment of patients with multiple myeloma(MM).Methods A total of 79 patients with MM admitted during March 2016 and October 2018 were divided into control group(n=39)and observation group(n=40)according to therapeutic methods.Both groups were treated with Dexamethasone,and then control group was treated with Bortezomib,while observation group was treated with Ralidomide.In two groups,therapeutic effects were observed,and changes of erythrocyte,hemoglobin,leukocyte and platelet,serum creatinine,serum M protein and bone marrow plasma cells were compared,and adverse drug reactions were also evaluated.Results The total effective rate in observation group was significantly higher than that in control group(P<0.05).After treatment,levels of hemoglobin,erythrocyte and platelet were significantly higher,while levels of serum creatinine,serum M protein and bone marrow plasma cells were significantly lower than those before treatment in both groups;the improvement conditions in observation group were better than those in control group(P<0.05).There was no significant difference in incidence rate of adverse drug reactions between two groups.Conclusion Ralidomide combined with Dexamethasone is effective in treatment of patients with multiple myeloma.

关 键 词：多发性骨髓瘤 雷利度胺 地塞米松 血肌酐 血清M蛋白 骨髓浆细胞 

分 类 号：R733.3[医药卫生—肿瘤]